A new micro Sweat Test Patch is being studied as a point of care method to monitor CFTR function in people with cystic fibrosis within a multicenter study currently. The device, described as a micro Sweat Test Patch or mSTP, aims to deliver sweat chloride readouts at the bedside and to complement standard sweat testing used in the study as the comparator. The project is listed in the ClinicalTrials.gov record NCT07414810 and is supported by Emory University, Georgia Institute of Technology, and the Consortium for Technology and Innovation in Pediatrics. The status shown in the record is not yet recruiting, indicating early stage development and regulatory review. For more details see the ClinicalTrials.gov record above.
What changed in CFTR monitoring tools
The CFTR function monitoring landscape gains a new option designed for sweat chloride testing at the point of care. The micro Sweat Test Patch described in the registry is intended to measure chloride levels in sweat and to provide clinicians with user friendly access to functional readouts in a clinical setting. In the current study design the patch is used alongside standard sweat testing, which serves as the comparator to evaluate performance. The involved sponsors are listed on the trial record, and the status is not yet recruiting, signaling early development and a regulatory planning phase that will require further data before any decision on broader use is made. Clinicians and regulators alike will watch how the performance metrics align with established sweat testing standards.
What is the device and how is it used?
The micro Sweat Test Patch is a device intended to be applied to the skin to facilitate sweat collection and chloride measurement as a proxy for CFTR function. In the study protocol the patch is positioned to run in parallel with standard sweat testing to assess concordance and potential advantages in clinical workflow. The device is presented within a framework that emphasizes point of care testing and patient friendly access to CFTR function information, with the standard of care sweat testing (SOC) used for comparison. The description reflects sponsor statements and trial context rather than a finished product claim, underscoring the need for rigorous evaluation under regulatory expectations. For additional context the trial record is accessible via ClinicalTrials.gov.
Who sponsors and what is the trial status?
The study is sponsored by Emory University, Georgia Institute of Technology, and The Consortium for Technology and Innovation in Pediatrics (CTIP). As of February 19, 2026, the record lists the trial as not yet recruiting, indicating that participant recruitment has not begun and that the project remains in early development with regulatory and oversight steps pending. This sponsorship pattern highlights collaboration across academic institutions with an emphasis on pediatric innovation and CF care, while maintaining a cautious path toward potential future regulatory clearance should data demonstrate meaningful safety and performance benefits.
What are the regulatory considerations and safety notes?
The information in the record reflects ongoing research in CFTR function monitoring using a dedicated device and standard comparison testing. In line with MDR style expectations, the documents emphasize intended use, performance parameters, and safety considerations as part of an early stage investigation. The final regulatory status will depend on the accumulation of robust performance data and risk management evidence, with outcomes that could influence future use in clinical practice if the device demonstrates clear benefits and an acceptable safety profile. The description here is based on the sponsor oriented documentation and does not constitute regulatory approval.
FAQ
- 1. What is the micro Sweat Test Patch The mSTP is a device studied for sweat chloride testing to monitor CFTR function in cystic fibrosis.
- 2. How is sweat chloride used in this context Sweat chloride serves as a biomarker that reflects CFTR function and is used to monitor disease related changes in a research setting.
- 3. Who is sponsoring the study Emory University, Georgia Institute of Technology and the Consortium for Technology and Innovation in Pediatrics sponsor the project.
- 4. What is the current trial status The record lists not yet recruiting as the status, indicating early development phases and ongoing regulatory review.
- 5. How could this affect CF care If demonstrated safe and effective, a point of care patch could complement standard testing and provide rapid functional information to support clinical decisions.
Conclusion and implications
The emergence of a micro Sweat Test Patch for CFTR function monitoring signals a potential shift toward bedside functional testing in cystic fibrosis care. The current evidence base relies on a single trial record with not yet recruiting status, underscoring the need for further data before any clinical adoption. Regulators and clinicians should monitor the outcome measures proposed in the protocol and assess how the patch performs in comparison with standard sweat testing. The collaboration between academic centers emphasizes a patient focused approach to pediatric CF care and aligns with ongoing regulatory pathways that govern new diagnostic tools.
Disclaimer
This article is intended for professionals engaged in regulatory, quality and clinical activities. It is not legal advice and does not replace guidance from regulatory authorities. All statements reflect the source text and cited references as of the publication date.
Announcement details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07414810?term=medical+device